アフェレーシス装置の世界市場予測（2028年まで）：製品別・処置別・技術別・流通チャネル別・用途別・地域別の分析

世界のアフェレーシス装置の市場規模は、2021年に20億3,000万米ドルとなり、2028年までに43億5,000万米ドルに達し、予測期間中に11.5％のCAGRで成長すると予測されています。

当レポートでは、世界のアフェレーシス装置市場について調査分析し、市場動向分析、セグメント別・地域別の市場情報、企業プロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

• 促進要因
• 抑制要因
• 市場機会
• 脅威
• 製品分析
• 技術分析
• 用途分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

第5章 世界のアフェレーシス装置市場：処置別

• 赤血球アフェレーシス（赤血球）
• 体外免疫吸着（ECI）
• 白血球アフェレーシス
• 低密度リポタンパク質（LDL）アフェレーシス
• 体外循環光療法
• プラズマフェレーシス（血漿）
• 血小板フェレーシス（血小板）
• 治療用サイタフェレーシス装置
• その他の手順

第6章 世界のアフェレーシス装置市場：製品別

• アフェレーシス機
• 使い捨てアフェレーシスキット
• 血漿および成分分離器

第7章 世界のアフェレーシス装置市場：技術別

• 膜ろ過
• 遠心分離
  • 連続フロー遠心分離
  • 断続フロー遠心分離

第8章 世界のアフェレーシス装置市場：流通チャネル別

• 直販
• 小売

第9章 世界のアフェレーシス装置市場：用途別

• 採血
• 治療目的
  • 自己免疫疾患
  • 心血管障害
  • 血液学
  • 神経学
  • 腎疾患

第10章 世界のアフェレーシス装置市場：エンドユーザー別

• 外来手術センター
• 血液銀行・献血センター
• 透析センター
• 病院・クリニック

第11章 世界のアフェレーシス装置市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東・アフリカ

第12章 主な発展

• 契約・パートナーシップ・提携・共同事業
• 買収・合併
• 新製品発売
• 拡張
• その他の重要な戦略

第13章 企業プロファイル

• Asahi Kasei Corporation
• B. Braun
• Baxter International Inc
• Cerus Corporation
• Fenwal
• Fresenius
• Haemonetics
• HemaCare
• KANEKA MEDIX CORPORATION
• Kawasumi Laboratories, Incorporated
• Medica S.p.A
• Medicap Inc
• Terumo BCT
• Therakos

List of Tables

• Table 1 Global Apheresis Equipment Market Outlook, By Region (2020-2028) ($MN)
• Table 2 Global Apheresis Equipment Market Outlook, By Procedure (2020-2028) ($MN)
• Table 3 Global Apheresis Equipment Market Outlook, By Erythrocytapheresis (Red Blood Cells) (2020-2028) ($MN)
• Table 4 Global Apheresis Equipment Market Outlook, By Extracorporeal Immunoadsorption (ECI) (2020-2028) ($MN)
• Table 5 Global Apheresis Equipment Market Outlook, By Leukapheresis (2020-2028) ($MN)
• Table 6 Global Apheresis Equipment Market Outlook, By Low-Density Lipoprotein (LDL) Apheresis (2020-2028) ($MN)
• Table 7 Global Apheresis Equipment Market Outlook, By Photopheresis (2020-2028) ($MN)
• Table 8 Global Apheresis Equipment Market Outlook, By Plasmapheresis (Plasma) (2020-2028) ($MN)
• Table 9 Global Apheresis Equipment Market Outlook, By Plateletpheresis (Platelets) (2020-2028) ($MN)
• Table 10 Global Apheresis Equipment Market Outlook, By Therapeutic Cytapheresis Equipment (2020-2028) ($MN)
• Table 11 Global Apheresis Equipment Market Outlook, By Other Procedures (2020-2028) ($MN)
• Table 12 Global Apheresis Equipment Market Outlook, By Product (2020-2028) ($MN)
• Table 13 Global Apheresis Equipment Market Outlook, By Apheresis Machine (2020-2028) ($MN)
• Table 14 Global Apheresis Equipment Market Outlook, By Disposable Apheresis Kits (2020-2028) ($MN)
• Table 15 Global Apheresis Equipment Market Outlook, By Plasma and Component Separator (2020-2028) ($MN)
• Table 16 Global Apheresis Equipment Market Outlook, By Technology (2020-2028) ($MN)
• Table 17 Global Apheresis Equipment Market Outlook, By Membrane Filtration (2020-2028) ($MN)
• Table 18 Global Apheresis Equipment Market Outlook, By Centrifugation (2020-2028) ($MN)
• Table 19 Global Apheresis Equipment Market Outlook, By Continuous Flow Centrifugation (2020-2028) ($MN)
• Table 20 Global Apheresis Equipment Market Outlook, By Intermittent Flow Centrifugation (2020-2028) ($MN)
• Table 21 Global Apheresis Equipment Market Outlook, By Distribution Channel (2020-2028) ($MN)
• Table 22 Global Apheresis Equipment Market Outlook, By Direct (2020-2028) ($MN)
• Table 23 Global Apheresis Equipment Market Outlook, By Retail (2020-2028) ($MN)
• Table 24 Global Apheresis Equipment Market Outlook, By Application (2020-2028) ($MN)
• Table 25 Global Apheresis Equipment Market Outlook, By Blood Collection (2020-2028) ($MN)
• Table 26 Global Apheresis Equipment Market Outlook, By Therapeutic Purpose (2020-2028) ($MN)
• Table 27 Global Apheresis Equipment Market Outlook, By Autoimmune Disorders (2020-2028) ($MN)
• Table 28 Global Apheresis Equipment Market Outlook, By Cardiovascular Disorders (2020-2028) ($MN)
• Table 29 Global Apheresis Equipment Market Outlook, By Hematology (2020-2028) ($MN)
• Table 30 Global Apheresis Equipment Market Outlook, By Neurology (2020-2028) ($MN)
• Table 31 Global Apheresis Equipment Market Outlook, By Renal Diseases (2020-2028) ($MN)
• Table 32 Global Apheresis Equipment Market Outlook, By End User (2020-2028) ($MN)
• Table 33 Global Apheresis Equipment Market Outlook, By Ambulatory Surgical Centers (2020-2028) ($MN)
• Table 34 Global Apheresis Equipment Market Outlook, By Blood Banks/Blood Donation Centers (2020-2028) ($MN)
• Table 35 Global Apheresis Equipment Market Outlook, By Dialysis Centres (2020-2028) ($MN)
• Table 36 Global Apheresis Equipment Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

According to Stratistics MRC, the Global Apheresis Equipment Market is accounted for $2.26 billion in 2022 and is expected to reach $4.35 billion by 2028 growing at a CAGR of 11.5% during the forecast period. Apheresis is a procedure in which blood is temporarily taken from a donor and separated into its components. The necessary components, such as plasma or platelets, are retained and the remaining blood is returned to the donor by transfusion. Platelets are used to treat various diseases and are extracted with apheresis equipment. It finds application in blood banks and the treatment of various medical conditions. In recent years, the introduction of modern apheresis equipment has led to the development of advanced features, such as auto elutriation and fluid flow dynamics, and has enabled the collection of platelets or red blood cells (RBCs) concentrates.

As per the Centers for Disease Control and Prevention (CDC), in 2021, it was estimated that about 37 million (15%) adults in the United States had chronic kidney disease (CKD). Apheresis plays a vital role in blood purification in patients with kidney disorders and drives the market studied. Along with these factors, the increasing product innovations and approvals have been driving market growth.

Market Dynamics:

Driver:

Growing utilization in different types of procedures

There are different types of procedures depending upon the constituents of blood undergoing centrifugation i.e. the components being separated and withdrawn such as Plasma (plasmapheresis), Platelets (plateletpheresis), Leukocytes (leukapheresis), Lymphocytes (lymphopheresis or lymphapheresis) and Red blood cells (erythropheresis). Whereas the procedures also has many therapeutic applications in which the diseased component of the blood is removed while the healthy component is returned back to the patient's circulation. In addition ti this the procedure can also be used in stem cell harvesting. Apheresis equipment market is growing, this is attributed to increasing usage of this equipment during blood donation also the equipment is used in many diseases such as severe cryoglobulinemia, Guillain-Barre (GB) syndrome, homozygous familial hypercholesterolemia, myasthenia gravis, fulminant Wilson disease etc. In addition to this, apheresis procedure is also used as second line treatment in many other conditions.

Restraint:

High investment

The high financial cost of the apheresis procedure and equipment as well as the huge capital investment required estimated to hinder the market growth. Huge Research and Development costs are entailed for manufacturing the product followed by the marketing costs. The risk associated with apheresis includes a tendency to bleed as the clotting factor is removed, low blood pressure owing to removal of fluids, susceptibility to infections on account of the removal of antibodies, and anticoagulant reactions. The lack of highly trained and competent apheresis operators continues to impede market growth.

Opportunity:

Growing inclination for blood components

Blood is necessary for the human body's health and survival. The demand for blood components is rising on account of the increasing rate of blood transfusions for chronic blood conditions and surgeries, the increasing prevalence of chronic diseases in the elderly population, and rising incidence rates of cancer. According to American red Cross, approximately 29,000 units of red blood cells are needed every day in the U. S. red blood cells are used to cure anemia which develops when your blood lacks enough healthy red blood cells to carry oxygen to body tissues. It affects more than 3 million Americans, according to the National Heart, Lung, and Blood Institute. Platelet transfusions are required for patients with chronic diseases such as liver disease and myelofibrosis. Platelet count tends to decline below normal as this disease advances and platelet function becomes impaired. There's been increasing demand for platelet-rich plasma owing to the rising number of road accidents and trauma cases, driving the market growth.

Threat:

Disruptions due to pandemic

The global apheresis equipment market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement.

COVID-19 Impact

The apheresis market was expected to be positively impacted during the COVID-19 pandemic due to the extensive application of plasma therapy to treat patients infected with COVID-19. Furthermore, in August 2020, the US FDA granted emergency use authorization (EUA) for convalescent plasma (CCP) therapy in hospitalized individuals with COVID-19. Also, in April 2020, Terumo BCT Inc. and Marker Therapeutics AG received the FDA approval for the Emergency Use Authorization (EUA) of Terumo BCT's Spectra Optia Apheresis System combined with Marker Therapeutics' D2000 Adsorption Cartridge to treat patients aged 18 years and above with confirmed COVID-19 disease.

The centrifugation segment is expected to be the largest during the forecast period

The centrifugation segment is estimated to have a lucrative growth. Centrifugation is an extremely efficacious procedure which facilitates in attaining the extraction rate of the blood plasma up to 80%. The procedure can be carried out as a continuous flow or intermittent flow and necessitates lower rates of the blood flow, enabling it to be executed with the help of central venous access or peripheral venous access. The Continuous Flow centrifugation is capable of operating with simultaneous functions of separating, processing and re-infusing the blood components. The multi-functionality allows for saving time significantly but require two vascular access sites. It is advantageous over the Intermittent Flow centrifugation procedure which involves recurrent cycles of blood drawing, separating, processing and re-infusion. It consumes much longer time using only one vascular access site.

The plasmapheresis (plasma) segment is expected to have the highest CAGR during the forecast period

The plasmapheresis (plasma) segment is anticipated to witness the fastest CAGR growth during the forecast period owing to its use for treating covid patients, increasing autoimmune disorders and neurological diseases. Plasmapheresis is a method for removing blood plasma from the body that involves drawing blood, separating it into plasma and cells, and then restoring the cells into the bloodstream. During the pandemic, plasmapheresis was used to extract convalescent plasma. Plasma from individuals who have recovered from an infection is known as convalescent plasma. Antibodies to the infection virus are present in this plasma. Antibodies are proteins produced by the immune system following an infection that can neutralize or kill the virus while also aiding in recovery, thereby driving the segment growth.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Increasing prevalence of blood disorders requiring plasma and platelet transfusion in the emerging markets of India and China is one of the key factors accounting for this growth in revenue share. The healthcare infrastructure has undergone remarkable changes and upgradation. It has shown readiness in adoption of the advanced technologies and medical devices. It has been home to numerous innovations in the field of novel drug therapeutics and patient-centred treatments. Furthermore, improving healthcare infrastructure and increasing number of healthcare practitioners in the Asia Pacific region is expected to present the industry with a robust growth rate during the forecast period.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period owing to the presence of sophisticated healthcare infrastructure and high patient awareness levels coupled with relatively higher healthcare expenditure. The region is in the forefront of the innovation and developments in the healthcare arena. It benefits from the key industrial players who have headquarters in the states of U.S and Canada. These countries being the focal points of development, the favourable regulatory scenario and the continuous support of the government have played a key role in their development. According to the American Red Cross Society Each year, an estimated 6.8 million people in the U.S. donate blood. Relatively larger number of R&D exercises pertaining to product manufacturing and marketing activities in the region also boosts the market growth.

Key players in the market

Some of the key players profiled in the Apheresis Equipment Market include Asahi Kasei Corporation, B. Braun, Baxter International Inc, Cerus Corporation, Fenwal, Fresenius, Haemonetics, HemaCare, KANEKA MEDIX CORPORATION, Kawasumi Laboratories, Incorporated, Medica S.p.A, Medicap Inc, Terumo BCT, and Therakos.

Key Developments:

In January 2020, Fresenius Kabi, which is a global healthcare company announced expansion of apheresis disposables and plant worth €30 million in Dominican Republic. The plant expansion will help the company to maintain its position as a leading global exporter of apheresis and plasma collecting equipment.

In July 2020, Haemonetics Corporation announced that it had entered into an agreement with Abenex to sell its full-owned subsidiary Inlog Holdings France SAS to the latter company. The transaction is projected to close by the end of the Third quarter of 2020.

In October 2021, Terumo Blood and Cell Technologies expanded its production capacity by opening a new manufacturing facility in Costa Rica worth $60 million USD. The Costa Rica plant will help to expand the production of Spectra Optia Apheresis System besides other products and support its global supply chain spanning 130 countries.

In July 2021, Terumo Blood and Cell Technologies, specialized in blood component, therapeutic apheresis and cellular technologies expanded the functionality of Spectra Optia, therapeutic apheresis, cell processing, and cell collection platform, with an accessory device, the UVA PIT System to perform extracorporeal photopheresis immunotherapy (ECP) procedures at the patient's bedside.

Procedures Covered:

• Erythrocytapheresis (Red Blood Cells)
• Extracorporeal Immunoadsorption (ECI)
• Leukapheresis
• Low-Density Lipoprotein (LDL) Apheresis
• Photopheresis
• Plasmapheresis (Plasma)
• Plateletpheresis (Platelets)
• Therapeutic Cytapheresis Equipment
• Other Procedures

Products Covered:

• Apheresis Machine
• Disposable Apheresis Kits
• Plasma and Component Separator

Technologies Covered:

• Membrane Filtration
• Centrifugation

Distribution Channels Covered:

• Direct
• Retail

Applications Covered:

• Blood Collection
• Therapeutic Purpose

End Users Covered:

• Ambulatory Surgical Centers
• Blood Banks/Blood Donation Centers
• Dialysis Centres
• Hospitals & Clinics

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Apheresis Equipment Market, By Procedure

• 5.1 Introduction
• 5.2 Erythrocytapheresis (Red Blood Cells)
• 5.3 Extracorporeal Immunoadsorption (ECI)
• 5.4 Leukapheresis
• 5.5 Low-Density Lipoprotein (LDL) Apheresis
• 5.6 Photopheresis
• 5.7 Plasmapheresis (Plasma)
• 5.8 Plateletpheresis (Platelets)
• 5.9 Therapeutic Cytapheresis Equipment
• 5.10 Other Procedures

6 Global Apheresis Equipment Market, By Product

• 6.1 Introduction
• 6.2 Apheresis Machine
• 6.3 Disposable Apheresis Kits
• 6.4 Plasma and Component Separator

7 Global Apheresis Equipment Market, By Technology

• 7.1 Introduction
• 7.2 Membrane Filtration
• 7.3 Centrifugation
  • 7.3.1 Continuous Flow Centrifugation
  • 7.3.2 Intermittent Flow Centrifugation

8 Global Apheresis Equipment Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Direct
• 8.3 Retail

9 Global Apheresis Equipment Market, By Application

• 9.1 Introduction
• 9.2 Blood Collection
• 9.3 Therapeutic Purpose
  • 9.3.1 Autoimmune Disorders
  • 9.3.2 Cardiovascular Disorders
  • 9.3.3 Hematology
  • 9.3.4 Neurology
  • 9.3.5 Renal Diseases

10 Global Apheresis Equipment Market, By End User

• 10.1 Introduction
• 10.2 Ambulatory Surgical Centers
• 10.3 Blood Banks/Blood Donation Centers
• 10.4 Dialysis Centres
• 10.5 Hospitals & Clinics

11 Global Apheresis Equipment Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Asahi Kasei Corporation
• 13.2 B. Braun
• 13.3 Baxter International Inc
• 13.4 Cerus Corporation
• 13.5 Fenwal
• 13.6 Fresenius
• 13.7 Haemonetics
• 13.8 HemaCare
• 13.9 KANEKA MEDIX CORPORATION
• 13.10 Kawasumi Laboratories, Incorporated
• 13.11 Medica S.p.A
• 13.12 Medicap Inc
• 13.13 Terumo BCT
• 13.14 Therakos